ABIONYX Pharma Logo

ABIONYX Pharma

Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.

ABNX | PA

Overview

Corporate Details

ISIN(s):
FR0012616852 (+1 more)
LEI:
969500785J7VIC5YPC96
Country:
France
Address:
33 AVENUE GEORGES POMPIDOU, 31130 BALMA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ABIONYX Pharma is a new-generation biotechnology company focused on discovering and developing innovative therapies for diseases with no existing or effective treatments, including rare conditions. The company specializes in creating drugs for renal and ophthalmological diseases. It leverages its expertise in lipid science to develop novel treatments, including new High-Density Lipoprotein (HDL) vectors for targeted drug delivery and apolipoprotein A-I (apoA-I)-based therapeutics.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-25 18:58
Interim Report
Rapports financiers et d'audit semestriels/examens réduits / Rapport financier …
French 1.0 MB
2025-08-28 18:51
Earnings Release
Inside Information / Other news releases
English 303.6 KB
2025-08-28 18:51
Earnings Release
Informations privilégiées / Autres communiqués
French 336.5 KB
2025-08-27 19:26
M&A Activity
Informations privilégiées / Autres communiqués
French 274.8 KB
2025-08-27 19:26
M&A Activity
Inside Information / Other news releases
English 236.5 KB
2025-07-04 18:42
Declaration of Voting Results & Voting Rights Announcements
Total number of voting rights and capital / Information on the total number of …
English 217.2 KB
2025-07-04 18:42
Declaration of Voting Results & Voting Rights Announcements
Total du nombre de droits de vote et du capital / Information relative au nombr…
French 198.1 KB
2025-07-03 19:35
Transaction in Own Shares
Acquisition ou cession des actions de l'émetteur / Information relative au cont…
French 532.3 KB
2025-07-03 19:35
Capital/Financing Update
Acquisition or disposal of the issuer's own shares / Information relating to th…
English 557.0 KB
2025-06-27 19:14
Post-Annual General Meeting Information
Inside Information / Other news releases
English 206.8 KB
2025-06-27 19:14
Post-Annual General Meeting Information
Informations privilégiées / Autres communiqués
French 221.2 KB
2025-06-06 18:15
Pre-Annual General Meeting Information
Modalités de mise à disposition des documents préparatoires à l'AG
French 273.9 KB
2025-06-03 18:00
Declaration of Voting Results & Voting Rights Announcements
Total du nombre de droits de vote et du capital / Information relative au nombr…
French 198.3 KB
2025-06-03 18:00
Declaration of Voting Results & Voting Rights Announcements
Total number of voting rights and capital / Information on the total number of …
English 218.9 KB
2025-05-28 18:00
Earnings Release
Quarterly financial reporting / First quarter financial report
English 315.4 KB

Automate Your Workflow. Get a real-time feed of all ABIONYX Pharma filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for ABIONYX Pharma via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-02-28 N/A Other Buy 53,913 N/A

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden ACUC

Talk to a Data Expert

Have a question? We'll get back to you promptly.